The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

The Trump administration aims to issue a rule empowering regulators to “forcefully” go after companies that don’t share drug ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines given in the U.S. this ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

The GOP senator objected to Secretary Kennedy's recasting of the influential advisory panel, which has sparked criticism from ...

The reported dismissal of high-ranking CBER officials Nicole Verdun and Rachael Anatol resurfaced lingering concerns about ...

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...

HHS rehired more than 700 workers at the CDC and over 200 employees at the NIH after restructuring this spring, HHS Secretary ...